Insider transactions

EDGAR

MBX Biosciences, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
1 transactions, 18,500 shares
Sum of shares × price per share: 525,662.7
Open-market sales (code S)
7 transactions, 76,477 shares
Sum of shares × price per share: 3,022,965.66

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–37 of 37

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-10 Filed 2026-11-12Hoerter Steven L. Director · Officer: Chairman, President and CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,89354.82
268,234.26

Derived: shares × price per share. Exact value 268234.26.

78,045Direct (D) No
F1, F2
  • F1 The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $51.52 to $55.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-457015 Read from the filing’s XML Dispute this row
2026-11-04 Filed 2026-11-05Azoulay Salomon Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)37353.96
20,127.08

Derived: shares × price per share. Exact value 20127.08.

14,026Direct (D) No
F1, F2
  • F1 The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold on an aggregate basis for all Company participants, at prices ranging from $51.78 to $56.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-449832 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-22Radovich Peter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (18,200) — exercise price 53.50
Acquired (A)18,2000—18,200Direct (D) No
F1
  • F1 One-third of the shares underlying this option will vest and become exercisable on October 20, 2027, the anniversary of the date of grant, with the remainder vesting monthly over the subsequent two year period, subject to the Reporting Person's continued service on each such vesting date.
Open filing 0001193125-26-428390 Read from the filing’s XML Dispute this row
2026-08-04 Filed 2026-08-05Azoulay Salomon Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)37065.77
24,334.9

Derived: shares × price per share. Exact value 24334.90.

14,399Direct (D) No
F1, F2
  • F1 The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold on an aggregate basis for all Company participants, at prices ranging from $65.21 to $66.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-335373 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-04Hoerter Steven L. Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)71,0000—82,938Direct (D) No
F1
  • F1 Represents the grant of restricted stock units (RSUs). 25% of the shares subject to the RSU grant will vest annually over four years, on each July 13, 2027, 2028, 2029 and 2030, subject to continued service on each such vesting date.
Open filing 0001193125-26-331639 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-04Hoerter Steven L. Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (331,000) — exercise price 64.41
Acquired (A)331,0000—331,000Direct (D) No
F3
  • F3 The options will vest and become exercisable with 25% of the shares subject to the award vesting on July 13, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each such vesting date.
Open filing 0001193125-26-331639 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-04Smither John W Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)28,0000—28,000Direct (D) No
F1
  • F1 Represents the grant of restricted stock units (RSUs). 25% of the shares subject to the RSU grant will vest annually over four years, on each July 13, 2027, 2028, 2029 and 2030, subject to continued service on each such vesting date.
Open filing 0001193125-26-331642 Read from the filing’s XML Dispute this row
2026-08-03 Filed 2026-08-04Smither John W Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (130,000) — exercise price 64.41
Acquired (A)130,0000—130,000Direct (D) No
F2
  • F2 The options will vest and become exercisable with 25% of the shares subject to the award vesting on July 13, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each such vesting date.
Open filing 0001193125-26-331642 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Aynechi Tiba Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (12,500) — exercise price 30.91
Acquired (A)12,5000—12,500Direct (D) No
F1
  • F1 The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.
Open filing 0001193125-26-258420 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Ryder Steven Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (12,500) — exercise price 30.91
Acquired (A)12,5000—12,500Direct (D) No
F1
  • F1 The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.
Open filing 0001193125-26-258422 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Mathers Edward T Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (12,500) — exercise price 30.91
Acquired (A)12,5000—12,500Direct (D) No
F1
  • F1 The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.
Open filing 0001193125-26-259236 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Stelzer Laurie Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (12,500) — exercise price 30.91
Acquired (A)12,5000—12,500Direct (D) No
F1
  • F1 The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.
Open filing 0001193125-26-258432 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Hoerter Steven L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (12,500) — exercise price 30.91
Acquired (A)12,5000—12,500Direct (D) No
F2
  • F2 The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.
Open filing 0001193125-26-258429 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Heron Patrick J Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (12,500) — exercise price 30.91
Acquired (A)12,5000—12,500Direct (D) No
F1
  • F1 The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.
Open filing 0001193125-26-258435 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Pescovitz Ora H. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (12,500) — exercise price 30.91
Acquired (A)12,5000—12,500Direct (D) No
F1
  • F1 The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.
Open filing 0001193125-26-258436 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-11Azoulay Salomon Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)55,00010.46
575,300

Derived: shares × price per share. Exact value 575300.00.

69,769Direct (D) Yes
F1
  • F1 The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026.
Open filing 0001193125-26-216704 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-11Azoulay Salomon Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)55,00038.38
2,110,900

Derived: shares × price per share. Exact value 2110900.00.

14,769Direct (D) Yes
F1, F2
  • F1 The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026.
  • F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.00 to $41.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-216704 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-11Azoulay Salomon Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)15,00316
240,048

Derived: shares × price per share. Exact value 240048.

29,772Direct (D) Yes
F1
  • F1 The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026.
Open filing 0001193125-26-216704 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-11Azoulay Salomon Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)15,00338.30
574,614.9

Derived: shares × price per share. Exact value 574614.90.

14,769Direct (D) Yes
F1, F3
  • F1 The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026.
  • F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.00 to $41.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-216704 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-11Azoulay Salomon Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock option (right to buy) — underlying Common Stock (55,000) — exercise price 10.46
Acquired (A)55,0000—194,540Direct (D) Yes
F4
  • F4 25% of the shares underlying this option vested and became exercisable on June 24, 2025, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Open filing 0001193125-26-216704 Read from the filing’s XML Dispute this row
2026-05-08 Filed 2026-05-11Azoulay Salomon Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock option (right to buy) — underlying Common Stock (15,003) — exercise price 16
Acquired (A)15,0030—30,008Direct (D) Yes
F5
  • F5 25% of the shares underlying this option vested and became exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Open filing 0001193125-26-216704 Read from the filing’s XML Dispute this row
2026-05-06 Filed 2026-05-08Hawryluk P. Kent Director · Officer: President CEO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)60729.54
17,930.78

Derived: shares × price per share. Exact value 17930.78.

727,667Direct (D) No
F1, F2
  • F1 The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold on an aggregrate basis for all Company participants, at prices ranging from $29.23 to $29.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregrate number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-214574 Read from the filing’s XML Dispute this row
2026-05-06 Filed 2026-05-08Azoulay Salomon Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)23129.54
6,823.74

Derived: shares × price per share. Exact value 6823.74.

14,769Direct (D) No
F1, F2
  • F1 The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold on an aggregate basis for all Company participants, at prices ranging from $29.23 to $29.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-214582 Read from the filing’s XML Dispute this row
2026-05-01 Filed 2026-05-04Hoerter Steven L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)11,9380—11,938Direct (D) No
F1
  • F1 Represents the grant of restricted stock units (RSUs). The RSUs will vest in full on November 6, 2026, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-202615 Read from the filing’s XML Dispute this row
2026-05-01 Filed 2026-05-04Hoerter Steven L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (74,249) — exercise price 29.78
Acquired (A)74,2490—74,249Direct (D) No
F3
  • F3 The grant will vest 50% upon grant date and the remaining 50% in equal monthly installments over a six-month period from the grant date, subject to the Reporting Person's continued services to the Company.
Open filing 0001193125-26-202615 Read from the filing’s XML Dispute this row
2026-03-13 Filed 2026-03-16Hawryluk P. Kent Director · Officer: President CEO
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)18,50028.4142
525,662.7

Derived: shares × price per share. Exact value 525662.7000.

486,777Indirect (I) By TrustNo
F1, F2
  • F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.28 to $28.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • F2 Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Open filing 0001193125-26-107268 Read from the filing’s XML Dispute this row
2026-02-26 Filed 2026-02-27Hawryluk P. Kent Director · Officer: President CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)28,76816.00
460,288

Derived: shares × price per share. Exact value 460288.00.

728,274Direct (D) No— Open filing 0001193125-26-082562 Read from the filing’s XML Dispute this row
2026-02-26 Filed 2026-02-27Hawryluk P. Kent Director · Officer: President CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock option (right to buy) — underlying Common Stock (28,768) — exercise price 16.00
Disposed (D)28,7680—91,668Direct (D) No
F2
  • F2 25% of the shares underlying this option vested and became exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Open filing 0001193125-26-082562 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-03Azoulay Salomon Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)15,0000—15,000Direct (D) No
F1
  • F1 Represents the grant of restricted stock units (RSUs). The RSUs will vest over a four (4) year period in equal quarterly installments, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-035587 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-03Azoulay Salomon Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (70,000) — exercise price 39.07
Acquired (A)70,0000—70,000Direct (D) No
F2
  • F2 The shares underlying this option vest and become exercisable in forty eight (48) equal monthly installments, beginning on March 2, 2026, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-035587 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-03Hawryluk P. Kent Director · Officer: President CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)35,2500—699,506Direct (D) No
F1
  • F1 Represents the grant of restricted stock units (RSUs). The RSUs will vest over a four (4) year period in equal quarterly installments, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-035582 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-03Hawryluk P. Kent Director · Officer: President CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (164,500) — exercise price 39.07
Acquired (A)164,5000—164,500Direct (D) No
F3
  • F3 The shares underlying this option vest and become exercisable in forty eight (48) equal monthly installments, beginning on March 2, 2026, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-035582 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-03Bartram Richard Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)15,0000—15,000Direct (D) No
F1
  • F1 Represents the grant of restricted stock units (RSUs). The RSUs will vest over a four (4) year period in equal quarterly installments, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-035584 Read from the filing’s XML Dispute this row
2026-02-02 Filed 2026-02-03Bartram Richard Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (70,000) — exercise price 39.07
Acquired (A)70,0000—70,000Direct (D) No
F2
  • F2 The shares underlying this option vest and become exercisable in forty eight (48) equal monthly installments, beginning on March 2, 2026, subject to the Reporting Person's continued service on such vesting date.
Open filing 0001193125-26-035584 Read from the filing’s XML Dispute this row
2026-01-20 Filed 2026-01-22Stelzer Laurie Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (32,000) — exercise price 43.14
Acquired (A)32,0000—32,000Direct (D) No
F1
  • F1 One-third of the shares underlying this option will vest and become exercisable on January 20, 2027, the anniversary of the date of grant, with the remainder vesting monthly over the subsequent two year period, subject to the Reporting Person's continued service on each such vesting date.
Open filing 0001193125-26-018702 Read from the filing’s XML Dispute this row
2025-11-22 Filed 2026-04-22Hoerter Steven L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (0) — exercise price 27.08
Acquired (A)00—0Direct (D) No
F1, F2
  • F1 Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $1,000,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.
  • F2 The grant will vest in equal monthly installments over a one-year period from November 6, 2025, subject to the non-employee director's continued services to the Company.
Open filing 0001193125-26-168530 Read from the filing’s XML Dispute this row
2025-11-22 Filed 2025-11-25Hoerter Steven L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (8,000) — exercise price 27.08
Acquired (A)8,0000—8,000Direct (D) No
F1
  • F1 The grant will vest in equal monthly installments over a one-year period from November 6, 2025, subject to the non-employee director's continued services to the Company.
Open filing 0001193125-25-294675 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–50 of 200

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
FMR LLC Partly reported under another manager7,368,420 SH431,936,786 dollarsHigher by 2,045,535 Prior quarter: 5,322,885Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Frazier Life Sciences Management, L.P. 6,652,013 SH389,941,002 dollarsUnchanged Prior quarter: 6,652,013Open filing 0001892134-26-000007 Filed 2026-11-16 Dispute this row
WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager5,164,535 SH302,745,043 dollarsHigher by 187,012 Prior quarter: 4,977,523Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row
Paradigm Biocapital Advisors LP 3,772,885 SH221,166,519 dollarsHigher by 1,264,870 Prior quarter: 2,508,015Open filing 0001855655-26-000020 Filed 2026-11-16 Dispute this row
NEA Management Company, LLC 3,614,486 SH211,881,169 dollarsUnchanged Prior quarter: 3,614,486Open filing 0001072613-26-000901 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager3,473,447 SH203,613,464 dollarsHigher by 149,775 Prior quarter: 3,323,672Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
ORBIMED ADVISORS LLC 3,074,853 SH180,247,883 dollarsLower by 353,883 Prior quarter: 3,428,736Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row
NVP ASSOCIATES, LLC 2,136,335 SH125,231,958 dollarsUnchanged Prior quarter: 2,136,335Open filing 0001545692-26-000013 Filed 2026-11-13 Dispute this row
Polar Capital Holdings Plc Partly reported under another manager1,603,582 SH94,001,977 dollarsLower by 4,932 Prior quarter: 1,608,514Open filing 0001172661-26-005169 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 1,430,897 SH83,879,182 dollarsLower by 46,491 Prior quarter: 1,477,388Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Aaron Wealth Advisors LLC 1,175,771 SH68,923,696 dollarsHigher by 7,972 Prior quarter: 1,167,799Open filing 0001172661-26-004505 Filed 2026-10-13 Dispute this row
Driehaus Capital Management LLC 1,012,698 SH59,364,357 dollarsLower by 43,881 Prior quarter: 1,056,579Open filing 0000938206-26-000066 Filed 2026-11-16 Dispute this row
Kynam Capital Management, LP 934,799 SH54,797,917 dollarsUnchanged Prior quarter: 934,799Open filing 0001907884-26-000017 Filed 2026-11-16 Dispute this row
EVENTIDE ASSET MANAGEMENT, LLC 873,492 SH51,204,101 dollarsUnchanged Prior quarter: 873,492Open filing 0001580642-26-007711 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager861,502 SH50,501,247 dollarsLower by 2,964 Prior quarter: 864,466Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager841,043 SH49,310,847 dollarsHigher by 67,971 Prior quarter: 773,072Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Parkman Healthcare Partners LLC 716,542 SH42,003,692 dollarsLower by 83,631 Prior quarter: 800,173Open filing 0001420506-26-002809 Filed 2026-11-16 Dispute this row
Woodline Partners LP 653,972 SH38,335,839 dollarsLower by 246,120 Prior quarter: 900,092Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row
TCG Crossover Management, LLC 650,000 SH38,103,000 dollarsUnchanged Prior quarter: 650,000Open filing 0001214659-26-014306 Filed 2026-11-16 Dispute this row
Deep Track Capital, LP 640,000 SH37,516,800 dollarsLower by 1,092,569 Prior quarter: 1,732,569Open filing 0001856083-26-000006 Filed 2026-11-16 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager621,624 SH36,441 dollarsLower by 193,183 Prior quarter: 814,807Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager425,555 SH24,946,035 dollarsLower by 33,450 Prior quarter: 459,005Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
BRAIDWELL LP 398,951 SH23,386,508 dollarsLower by 311,929 Prior quarter: 710,880Open filing 0001420506-26-002894 Filed 2026-11-16 Dispute this row
Cormorant Asset Management, LP Partly reported under another manager375,000 SH21,982,500 dollarsLower by 175,000 Prior quarter: 550,000Open filing 0001583977-26-000011 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 323,459 SH18,961,167 dollarsLower by 23,258 Prior quarter: 346,717Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
LORD, ABBETT CO. LLC 295,987 SH17,351 dollarsNot in the prior quarter’s filings read Open filing 0000930413-26-003314 Filed 2026-11-13 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager293,217 SH15,388,028 dollarsHigher by 40,552 Prior quarter: 252,665Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
Candriam S.C.A. 281,493 SH16,561,409 dollarsLower by 8,400 Prior quarter: 289,893Open filing 0001537014-26-000009 Filed 2026-11-03 Dispute this row
Rock Springs Capital Management LP 275,347 SH16,140,841 dollarsLower by 22,871 Prior quarter: 298,218Open filing 0001172661-26-005279 Filed 2026-11-16 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 270,858 SH15,877,696 dollarsHigher by 37,763 Prior quarter: 233,095Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager266,783 SH15,638,820 dollarsLower by 32,144 Prior quarter: 298,927Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager262,138 SH15,366,530 dollarsHigher by 15,460 Prior quarter: 246,678Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
Soleus Capital Management, L.P. 258,897 SH15,176,542 dollarsLower by 256,382 Prior quarter: 515,279Open filing 0001802630-26-000008 Filed 2026-11-16 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager232,413 SH13,624,050 dollarsLower by 1,287 Prior quarter: 233,700Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
UBS Group AG Partly reported under another manager227,768 SH13,351,760 dollarsLower by 44,979 Prior quarter: 272,747Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Tetragon Partners GP Ltd 220,647 SH12,934,327 dollarsHigher by 17,104 Prior quarter: 203,543Open filing 0000919574-26-008018 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 216,665 SH12,700,902 dollarsHigher by 15,236 Prior quarter: 201,429Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
MORGAN STANLEY Partly reported under another manager202,461 SH11,868,290 dollarsLower by 46,097 Prior quarter: 248,558Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Schonfeld Strategic Advisors LLC 158,104 SH9,268,056 dollarsLower by 90,566 Prior quarter: 248,670Open filing 0001665241-26-000003 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager147,600 SH8,652,312 dollarsHigher by 53,200 Prior quarter: 94,400Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
Invesco Ltd. Partly reported under another manager142,669 SH8,363,256 dollarsHigher by 91,991 Prior quarter: 50,678Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
BARCLAYS PLC Partly reported under another manager136,652 SH8,010,541 dollarsHigher by 48,798 Prior quarter: 87,854Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager135,720 SH7,837,830 dollarsLower by 3,891 Prior quarter: 139,611Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager127,305 SH7,462,619 dollarsLower by 55,462 Prior quarter: 182,767Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
KVP Capital Advisors, LP 121,524 SH7,123,737 dollarsUnchanged Prior quarter: 121,524Open filing 0001104659-26-127594 Filed 2026-11-16 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager113,023 SH6,625,408 dollarsLower by 288,862 Prior quarter: 401,885Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
TWO SIGMA INVESTMENTS, LP 112,075 SH6,569,837 dollarsLower by 1,400 Prior quarter: 113,475Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager107,568 SH6,305,634 dollarsNot in the prior quarter’s filings read Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
Burkehill Global Management, LP 100,000 SH5,862,000 dollarsUnchanged Prior quarter: 100,000Open filing 0001013594-26-001202 Filed 2026-11-16 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager84,522 SH4,954,687 dollarsLower by 4,405 Prior quarter: 88,927Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • EcoR1 Capital, LLC 388,500 SH
  • Sixth Street Partners Management Company, L.P. 233,095 SH
  • MILLENNIUM MANAGEMENT LLC 226,151 SH
  • Caption Management, LLC 200,000 SH
  • Caligan Partners LP 200,000 SH
  • PFM Health Sciences, LP 70,971 SH
  • OPTIMIZE FINANCIAL INC. 14,458 SH
  • Sound Capital Solutions LLC 14,458 SH
  • DAFNA Capital Management LLC 11,809 SH
  • Jupiter Topco LLC 10,300 SH
  • FRED ALGER MANAGEMENT, LLC 9,877 SH
  • Brevan Howard Capital Management LP 8,602 SH
  • ACT CAPITAL MANAGEMENT, LLC 8,000 SH
  • AXQ CAPITAL, LP 7,757 SH
  • XTX Topco Ltd 6,392 SH
  • SG Americas Securities, LLC 6,245 SH
  • INTECH INVESTMENT MANAGEMENT LLC 5,951 SH
  • Blackstone Inc. 5,533 SH
  • CANADA PENSION PLAN INVESTMENT BOARD 5,200 SH
  • Verdad Advisers, LP 4,574 SH
  • Goelzer Investment Management, Inc. 4,000 SH
  • State of Wyoming 1,055 SH
  • MERCER GLOBAL ADVISORS INC /ADV 553 SH
  • Aster Capital Management (DIFC) Ltd 172 SH
  • Integrated Wealth Concepts LLC 171 SH
  • Quarry LP 18 SH
  • NATIONAL BANK OF CANADA /FI/ 11 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Paradigm BioCapital Advisors LP Common Stock, $0.0001 par value per share7.83,772,885.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128295 Dispute this row
Paradigm BioCapital Advisors GP LLC Common Stock, $0.0001 par value per share7.83,772,885.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128295 Dispute this row
Senai Asefaw, M.D. Common Stock, $0.0001 par value per share7.83,772,885.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128295 Dispute this row
Paradigm BioCapital International Fund Ltd. Common Stock, $0.0001 par value per share6.93,324,531.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-128295 Dispute this row
FMR LLC COMMON STOCK15.07,224,009.1009/30/2026 Filed 2026-11-05SCHEDULE 13G/AAmendment 2Open filing 0000315066-26-002806 Dispute this row
Abigail P. Johnson COMMON STOCK15.07,224,009.1009/30/2026 Filed 2026-11-05SCHEDULE 13G/AAmendment 2Open filing 0000315066-26-002806 Dispute this row
ORBIMED ADVISORS LLC COMMON STOCK6.43,074,853.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0000947871-26-000776 Dispute this row
ORBIMED CAPITAL GP VII LLC COMMON STOCK5.22,505,150.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0000947871-26-000776 Dispute this row
ORBIMED GENESIS GP LLC COMMON STOCK1.2569,703.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0000947871-26-000776 Dispute this row
Frazier Life Sciences Public Fund, L.P. Common Stock, $0.0001 par value per share3.01,429,573.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0001231919-26-000851 Dispute this row
FHMLSP, L.P. Common Stock, $0.0001 par value per share3.01,429,573.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0001231919-26-000851 Dispute this row
FHMLSP, L.L.C. Common Stock, $0.0001 par value per share3.01,429,573.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0001231919-26-000851 Dispute this row
Frazier Life Sciences X, L.P. Common Stock, $0.0001 par value per share10.85,219,440.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0001231919-26-000851 Dispute this row
FHMLS X, L.P. Common Stock, $0.0001 par value per share10.85,219,440.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0001231919-26-000851 Dispute this row
FHMLS X, L.L.C. Common Stock, $0.0001 par value per share10.85,219,440.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0001231919-26-000851 Dispute this row
Frazier Life Sciences XI, L.P. Common Stock, $0.0001 par value per share0.03,000.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0001231919-26-000851 Dispute this row
FHMLS XI, L.P. Common Stock, $0.0001 par value per share0.03,000.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0001231919-26-000851 Dispute this row
FHMLS XI, L.L.C. Common Stock, $0.0001 par value per share0.03,000.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0001231919-26-000851 Dispute this row
James N. Topper Common Stock, $0.0001 par value per share11.75,219,440.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0001231919-26-000851 Dispute this row
Patrick J. Heron Common Stock, $0.0001 par value per share11.75,243,421.0008/06/2026 Filed 2026-08-10SCHEDULE 13D/AAmendment 3Open filing 0001231919-26-000851 Dispute this row
Deep Track Capital, LP Common Stock, $0.0001 par value per share3.641,732,569.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001172661-26-003482 Dispute this row
Deep Track Biotechnology Master Fund, Ltd. Common Stock, $0.0001 par value per share3.641,732,569.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001172661-26-003482 Dispute this row
David Kroin Common Stock, $0.0001 par value per share3.641,732,569.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001172661-26-003482 Dispute this row
BlackRock, Inc. Common Stock5.52,628,18106/30/2026 Filed 2026-07-29SCHEDULE 13GOpen filing 0002012383-26-002818 Dispute this row
FMR LLC COMMON STOCK11.25,322,884.6806/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-001474 Dispute this row
Abigail P. Johnson COMMON STOCK11.25,322,884.6806/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-001474 Dispute this row
Wellington Management Group LLP Common Stock10.54,977,523.0006/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 5Open filing 0000902219-26-000214 Dispute this row
Wellington Group Holdings LLP Common Stock10.54,977,523.0006/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 5Open filing 0000902219-26-000214 Dispute this row
Wellington Investment Advisors Holdings LLP Common Stock10.54,977,523.0006/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 5Open filing 0000902219-26-000214 Dispute this row
Wellington Management Company LLP Common Stock9.84,977,523.0006/30/2026 Filed 2026-07-08SCHEDULE 13G/AAmendment 5Open filing 0000902219-26-000214 Dispute this row
Paradigm BioCapital Advisors LP Common Stock, $0.0001 par value per share5.22,493,015.0006/16/2026 Filed 2026-06-24SCHEDULE 13GOpen filing 0001104659-26-077301 Dispute this row
Paradigm BioCapital Advisors GP LLC Common Stock, $0.0001 par value per share5.22,493,015.0006/16/2026 Filed 2026-06-24SCHEDULE 13GOpen filing 0001104659-26-077301 Dispute this row
Senai Asefaw, M.D. Common Stock, $0.0001 par value per share5.22,493,015.0006/16/2026 Filed 2026-06-24SCHEDULE 13GOpen filing 0001104659-26-077301 Dispute this row
Paradigm BioCapital International Fund Ltd. Common Stock, $0.0001 par value per share4.62,187,207.0006/16/2026 Filed 2026-06-24SCHEDULE 13GOpen filing 0001104659-26-077301 Dispute this row
FMR LLC COMMON STOCK6.22,936,684.0003/31/2026 Filed 2026-05-06SCHEDULE 13GOpen filing 0000315066-26-001256 Dispute this row
Abigail P. Johnson COMMON STOCK6.22,936,684.0003/31/2026 Filed 2026-05-06SCHEDULE 13GOpen filing 0000315066-26-001256 Dispute this row
BlackRock, Inc. Common Stock4.82,287,49703/31/2026 Filed 2026-04-27SCHEDULE 13G/AAmendment 1Open filing 0002012383-26-001704 Dispute this row
ORBIMED ADVISORS LLC COMMON STOCK7.73,637,887.0002/05/2026 Filed 2026-02-11SCHEDULE 13D/AAmendment 2Open filing 0000947871-26-000114 Dispute this row
ORBIMED CAPITAL GP VII LLC COMMON STOCK6.32,958,000.0002/05/2026 Filed 2026-02-11SCHEDULE 13D/AAmendment 2Open filing 0000947871-26-000114 Dispute this row
OrbiMed Genesis GP LLC COMMON STOCK1.4679,887.0002/05/2026 Filed 2026-02-11SCHEDULE 13D/AAmendment 2Open filing 0000947871-26-000114 Dispute this row
Wellington Management Group LLP Common Stock7.53,349,961.0012/31/2025 Filed 2026-02-10SCHEDULE 13G/AAmendment 4Open filing 0000902219-26-000071 Dispute this row
Wellington Group Holdings LLP Common Stock7.53,349,961.0012/31/2025 Filed 2026-02-10SCHEDULE 13G/AAmendment 4Open filing 0000902219-26-000071 Dispute this row
Wellington Investment Advisors Holdings LLP Common Stock7.53,349,961.0012/31/2025 Filed 2026-02-10SCHEDULE 13G/AAmendment 4Open filing 0000902219-26-000071 Dispute this row
Wellington Management Company LLP Common Stock7.33,349,961.0012/31/2025 Filed 2026-02-10SCHEDULE 13G/AAmendment 4Open filing 0000902219-26-000071 Dispute this row
BlackRock, Inc. Common Stock5.12,271,16112/31/2025 Filed 2026-01-21SCHEDULE 13GOpen filing 0002012383-26-000690 Dispute this row
New Enterprise Associates 17, L.P. Common Stock, par value $0.0001 per share8.13,614,486.0011/06/2025 Filed 2025-11-10SCHEDULE 13D/AAmendment 1Open filing 0001072613-25-000781 Dispute this row
NEA Partners 17, L.P. Common Stock, par value $0.0001 per share8.13,614,486.0011/06/2025 Filed 2025-11-10SCHEDULE 13D/AAmendment 1Open filing 0001072613-25-000781 Dispute this row
NEA 17 GP, LLC Common Stock, par value $0.0001 per share8.13,614,486.0011/06/2025 Filed 2025-11-10SCHEDULE 13D/AAmendment 1Open filing 0001072613-25-000781 Dispute this row
Forest Baskett Common Stock, par value $0.0001 per share8.13,614,486.0011/06/2025 Filed 2025-11-10SCHEDULE 13D/AAmendment 1Open filing 0001072613-25-000781 Dispute this row
Ali Behbahani Common Stock, par value $0.0001 per share8.13,614,486.0011/06/2025 Filed 2025-11-10SCHEDULE 13D/AAmendment 1Open filing 0001072613-25-000781 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,722,084 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015138,466
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to MBX Biosciences, Inc.